Open AccessPreferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample
Author(s) -
Karissa Johnston,
Jayson Stoffman,
A. Mickle,
Robert J. Klaassen,
D. Diles,
Shade Olatunde,
Lina Eliasson,
Roxana Bahar
Publication year - 2021
Publication title -
patient preference and adherence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.885
H-Index - 48
ISSN - 1177-889X
DOI - 10.2147/ppa.s316276
Subject(s) - medicine , vignette , bleed , snowball sampling , population , family medicine , descriptive statistics , pediatrics , surgery , environmental health , psychology , social psychology , pathology , statistics , mathematics
Current treatments for hemophilia A in Canada include on-demand treatment as bleeds occur and regular intravenous prophylactic factor VIII (FVIII) infusions. The subcutaneous therapy emicizumab was recently approved for treatment of hemophilia A. The objective of this study was to estimate utility values associated with hemophilia A health and treatment states from a Canadian societal perspective, including preferences related to treatment efficacy and frequency and route of administration.